Pembrolizumab + Sintilimab

This refers to a potential combination of two distinct PD-1 inhibitor drugs, pembrolizumab (Keytruda) and sintilimab (Tyvyt). According to the provided information, this is **not** an established or standard combination therapy. Both drugs are used individually or in combination with other treatments (e.g., chemotherapy) for various cancers, including non-small cell lung cancer (NSCLC). They target the same receptor (PD-1) but differ structurally. Comparative studies of the individual drugs (or regimens involving them) suggest they have generally comparable efficacy and safety profiles when used alone or in other combinations.